HumanexaHumanexaHumanexa
WelcomeSignalsCompaniesAssetsScenario AnalysisRegulatoryStrategy
InsightsNewslettersReportsBriefings
Pricing
WorkspaceTeamWatchlistsCollectionsSettings

Free

Intelligence Active

Addiction Medicine · Opioid Use Disorder Therapeutic Area Assessment

Intelligence report

Intelligence Report · ~15 min read

Addiction Medicine · Opioid Use Disorder Therapeutic Area Assessment

16 signals · 4 insights · 46 regulatory precedents

Type

Therapeutic Area Assessment

Generated

Jul 24, 2026

Confidence

Moderate Confidence · 67%

Evidence

66 items

Sources

3

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Therapeutic area assessment for Addiction Medicine · Opioid Use Disorder integrates 16 signals, 4 executive insights, and 46 regulatory precedents from the Humanexa intelligence graph. 0 portfolio assets maintain indication overlap in this area. Regulatory and competitive dynamics require cross-functional monitoring across linked entities.

Key Developments

Material intelligence events ranked by strategic relevance.

  1. signalJul 20, 2026

    University of Missouri-Columbia Launches Naloxone Training Initiative to Combat Opioid Overdoses

    The Opioid Rapid Response System (ORRS) project aims to train citizens in naloxone administration to reduce opioid overdose deaths.

    View detail
  2. signalJul 5, 2026

    Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression

    Preliminary results indicate that psilocybin-assisted psychotherapy significantly reduces drinking days and craving frequency in individuals with AUD and depressive symptoms.

    View detail
  3. signalJun 11, 2026

    FDA Clears Bridge Device for Opioid Use Disorder Treatment; Efficacy Under Evaluation

    The Bridge Device has received FDA clearance for the treatment of Opioid Use Disorder, emphasizing safety over efficacy.

    View detail
  4. signalJul 18, 2026

    Study on Oral Nicotine Pouches' Impact on Craving and Brain Response

    A study is underway to assess the effects of a 6 mg oral nicotine pouch on craving and brain responses to smoking cues.

    View detail
  5. regulatoryJul 20, 2026

    Guidance: Clinical trials for medicines: roles and responsibilities

    Which professions can act as an investigator, training and experience expectations, provision of medical support and delegation of activities.

    View detail
  6. regulatoryJul 20, 2026

    Training Course: Achieving Data Quality and Integrity in Maximum Containment Laboratories

    Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as opioid treatment pharma companies.

    View detail
  7. regulatoryJul 20, 2026

    [IBENTO][IBENTO]The report for the PMDA Asia office GMP Workshop Training 2026 has been posted.

    PMDA document relevant to the signal.

    View detail
  8. regulatoryJul 20, 2026

    Compounding Quality Center of Excellence | Instructor-Led Trainings

    The Compounding Quality Center of Excellence’s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.

    View detail
  9. insightJul 4, 2026

    Dr. Reddy's FDA Approval Reshapes Opioid Dependence Treatment Landscape

    The FDA's acceptance of Dr. Reddy's supplemental application for Buprenorphine and Naloxone is a significant regulatory milestone that could reshape competitive dynamics in the opioid dependence treatment market. This approval may allow Dr. Reddy's to gain market share against established players, necessitating strategic adjustments from competitors. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 7 ranked evidence items (3 high-relevance).

    View detail
  10. insightJun 29, 2026

    Potential Paradigm Shift in Opioid Use Disorder Treatment with XR-BUP

    The ongoing clinical trial for extended-release buprenorphine as a low-dose induction strategy could redefine treatment protocols for Opioid Use Disorder. Success in this trial may lead to significant shifts in clinical practice and competitive positioning within the addiction medicine landscape. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 9 ranked evidence items (4 high-relevance).

    View detail
  11. insightJun 19, 2026

    Innovative Approaches in Addiction Treatment: Digital Solutions and New Therapies

    This study is crucial as it explores the effectiveness of app-based incentives for older adults, a demographic often overlooked in addiction treatment. The findings could reshape product development and marketing strategies for pharma companies targeting substance use disorders, particularly in the digital therapeutic space. Regulatory context from FDA (FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia) supports the near-term read. Assessment grounded in 19 ranked evidence items (11 high-relevance).

    View detail
  12. insightJun 11, 2026

    FDA Clearance of Bridge Device Signals Regulatory Shift in OUD Treatment Landscape

    The FDA's clearance of the Bridge Device for Opioid Use Disorder highlights a significant regulatory milestone, but the lack of efficacy data raises concerns about its market adoption. Pharma strategy teams must closely monitor ongoing efficacy trials to gauge the device's long-term viability in a competitive landscape. Regulatory context from FDA (UPDATE: Hintermann Series H3 Total Ankle Replacement Has Higher-Than-Expected Risk of Device Failure: FDA Safety Communication) supports the near-term read. Assessment grounded in 10 ranked evidence items (3 high-relevance).

    View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Executive insights surface 4 risk-calibrated assessments for portfolio review. 46 Regunera precedents provide regulatory context for pathway and timing decisions. Monitor 3 companies with active signal exposure for competitive and portfolio shifts.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

  • Guidance: Clinical trials for medicines: roles and responsibilities

    83%

    Which professions can act as an investigator, training and experience expectations, provision of medical support and delegation of activities.

    Source: MHRA

    View evidence

  • Training Course: Achieving Data Quality and Integrity in Maximum Containment Laboratories

    72%

    Why this matters: sets a safety guidance precedent in the same sub-indication (pain) as opioid treatment pharma companies.

    Source: FDA

    View evidence

  • [IBENTO][IBENTO]The report for the PMDA Asia office GMP Workshop Training 2026 has been posted.

    72%

    PMDA document relevant to the signal.

    Source: PMDA

    View evidence

  • Compounding Quality Center of Excellence | Instructor-Led Trainings

    72%

    The Compounding Quality Center of Excellence’s free in-person training programs target outsourcing facility staff and offer continuing education credits. The training will open for state regulators and pharmacy compounders if space is available.

    Source: FDA

    View evidence

  • FDA AP — NALOXONE HYDROCHLORIDE AND PENTAZOCINE HYDROCHLORIDE (SUPPL)

    72%

    Application ANDA075523. Sponsor: SUN PHARM INDS LTD. Submission status: AP. Submission type: SUPPL. Active ingredients: NALOXONE HYDROCHLORIDE, PENTAZOCINE HYDROCHLORIDE.

    Source: FDA

    View evidence

  • Drug Trials Snapshots: PALSONIFY

    72%

    PALSONIFY is a somatostatin receptor analog for the treatment of adults with acromegaly who had an inadequate response to surgery and/or for whom surgery is not an option.

    Source: FDA

    View evidence

  • Dr. Reddy's FDA Approval Reshapes Opioid Dependence Treatment Landscape

    60%

    The FDA's acceptance of Dr. Reddy's supplemental application for Buprenorphine and Naloxone is a significant regulatory milestone that could reshape competitive dynamics in the opioid dependence treatment market. This approval may allow Dr. Reddy's to gain market share against established players, necessitating strategic adjustments from competitors. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 7 ranked evidence items (3 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Potential Paradigm Shift in Opioid Use Disorder Treatment with XR-BUP

    61%

    The ongoing clinical trial for extended-release buprenorphine as a low-dose induction strategy could redefine treatment protocols for Opioid Use Disorder. Success in this trial may lead to significant shifts in clinical practice and competitive positioning within the addiction medicine landscape. Regulatory context from FDA (FDA Broadens Access to Over-the-Counter Naloxone Nasal Spray for Opioid Overdose) supports the near-term read. Assessment grounded in 9 ranked evidence items (4 high-relevance).

    Source: Humanexa Insight

    View evidence

  • Innovative Approaches in Addiction Treatment: Digital Solutions and New Therapies

    91%

    This study is crucial as it explores the effectiveness of app-based incentives for older adults, a demographic often overlooked in addiction treatment. The findings could reshape product development and marketing strategies for pharma companies targeting substance use disorders, particularly in the digital therapeutic space. Regulatory context from FDA (FDA Approves First Treatment Shown to Reduce the Risk of Acute Pancreatitis in Adults with Severe Hypertriglyceridemia) supports the near-term read. Assessment grounded in 19 ranked evidence items (11 high-relevance).

    Source: Humanexa Insight

    View evidence

  • FDA Clearance of Bridge Device Signals Regulatory Shift in OUD Treatment Landscape

    55%

    The FDA's clearance of the Bridge Device for Opioid Use Disorder highlights a significant regulatory milestone, but the lack of efficacy data raises concerns about its market adoption. Pharma strategy teams must closely monitor ongoing efficacy trials to gauge the device's long-term viability in a competitive landscape. Regulatory context from FDA (UPDATE: Hintermann Series H3 Total Ankle Replacement Has Higher-Than-Expected Risk of Device Failure: FDA Safety Communication) supports the near-term read. Assessment grounded in 10 ranked evidence items (3 high-relevance).

    Source: Humanexa Insight

    View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

  • University of Missouri-Columbia Launches Naloxone Training Initiative to Combat Opioid Overdoses

    Trial Update

  • Psilocybin Shows Promise in Preventing Relapse in Alcohol Use Disorder with Depression

    Trial Update

  • FDA Clears Bridge Device for Opioid Use Disorder Treatment; Efficacy Under Evaluation

    Regulatory Approval

  • Study on Oral Nicotine Pouches' Impact on Craving and Brain Response

    Trial Update

  • Study on rTMS for Methamphetamine Abuse in Methadone Patients Launched

    Trial Update

  • Yale University develops culturally adapted CM for Black adults with stimulant use disorder

    Trial Update

  • FDA Approval Update for Buprenorphine and Naloxone from Dr. Reddy's Labs

    Regulatory Approval

  • Pilot Study on Opioid Use Disorder Treatment for Patients with Serious Injection Related Infections

    Trial Update

Insights

  • Dr. Reddy's FDA Approval Reshapes Opioid Dependence Treatment Landscape

    Addiction · Opioid Dependence

  • Potential Paradigm Shift in Opioid Use Disorder Treatment with XR-BUP

    Addiction Medicine · Opioid Use Disorder

  • Innovative Approaches in Addiction Treatment: Digital Solutions and New Therapies

    Addiction · Substance Use Disorders

  • FDA Clearance of Bridge Device Signals Regulatory Shift in OUD Treatment Landscape

    Addiction Medicine · Opioid Use Disorder

Companies

  • Pfizer

    140 signals

  • Dr. Reddy's

    8 signals

  • Dr. Reddy's Labs

    5 signals

PrivacyTermsRefund PolicyDisclaimerContact

© 2026 Humanexa. Intelligence for research workflows — not medical, legal, regulatory filing, or investment advice.